Daniel Rabinowitz, SEC and Chief Legal Officer of Natera, Inc. (NASDAQ: NTRA), disclosed the sale of 8,400 shares of the company's common stock on April 1, 2026, in a Form 4 filing with the Securities and Exchange Commission.
The transactions generated proceeds totaling $1.7 million. The filing lists weighted average prices for the sales as ranging from $200.7868 to $205.0026 per share.
The Form 4 shows the disposal occurred across multiple transactions at discrete price bands. The breakdown in the filing is as follows:
- 300 shares sold between $200.47 and $200.99;
- 1,778 shares sold between $201.4950 and $202.4700;
- 3,213 shares sold between $202.51 and $203.46;
- 1,200 shares sold between $203.52 and $204.25; and
- 1,909 shares sold between $204.54 and $205.50.
Following these sales, Rabinowitz retains direct ownership of 224,885 shares of Natera common stock. The filing notes that the sales were carried out under a Rule 10b5-1 trading plan the reporting person adopted on December 5, 2025.
Natera's share price has climbed 55% over the last year and is trading at $207.98, giving the company a market capitalization of $29.48 billion. According to InvestingPro analysis cited in the filing, the stock appears overvalued relative to its Fair Value estimate and is included on a Most Overvalued list.
The disclosure also references additional InvestingPro resources: InvestingPro subscribers reportedly have access to 8 additional exclusive tips for NTRA, along with Pro Research Reports that cover more than 1,400 U.S. equities.
Separate corporate developments disclosed around the same time highlight ongoing product and clinical activity at Natera. The company has introduced Zenith genomics, described as a whole genome sequencing test targeted at detecting rare genetic conditions. The new test uses advanced long-read sequencing technology and was developed in collaboration with MyOme, according to the disclosures.
Clinical data for the company's Signatera circulating tumor DNA assay were also cited. Studies on anal squamous cell carcinoma and locally advanced rectal cancer, published in Nature Communications, reportedly showed notable outcomes, including 100% one-year overall survival and 100% one-year progression-free survival for certain patient cohorts, underscoring the potential role of Signatera in cancer treatment monitoring.
On the governance front, Natera expanded its board by appointing Eric Rubin, increasing the board size to eleven members. The appointment was recommended by the Nominating, Corporate Governance and Compliance Committee, the company said.
In financial coverage changes, Morgan Stanley adjusted its model for Natera, reducing its stock price target to $250 from $265 while maintaining an Overweight rating on the shares.
Taken together, the insider sale, product launches, clinical publications, governance changes and analyst adjustments present a snapshot of Natera's current corporate and market activity. The Form 4 filing documents the specific insider transactions and the company's disclosures provide the accompanying operational and clinical context.